• Publications
  • Influence
Disrupting tumour blood vessels
Low-molecular-weight vascular-disrupting agents (VDAs) cause a pronounced shutdown in blood flow to solid tumours, resulting in extensive tumour-cell necrosis, while they leave the blood flow inExpand
  • 780
  • 31
The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells.
Combretastatin A-4-phosphate (CA-4-P) is a tubulin-binding compound currently in clinical trial as a tumor vascular-targeting agent. In endothelial cells, CA-4-P is known to cause microtubuleExpand
  • 255
  • 8
The biology of the combretastatins as tumour vascular targeting agents
The tumour vasculature is an attractive target for therapy. Combretastatin A‐4 (CA‐4) and A‐1 (CA‐1) are tubulin binding agents, structurally related to colchicine, which induce vascular‐mediatedExpand
  • 298
  • 8
Expression of vascular endothelial growth factor receptors in smooth muscle cells.
Vascular Endothelial Growth Factor (VEGF) has been typically considered to be an endothelial-specific growth factor. However, it was recently demonstrated that VEGF can interact with non endothelialExpand
  • 217
  • 7
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
  • C. Kanthou, G. Tozer
  • Biology, Medicine
  • International journal of experimental pathology
  • 1 June 2009
Vascular disrupting agents (VDAs) are a relatively new group of ‘vascular targeting’ agents that exhibit selective activity against established tumour vascular networks, causing severe interruptionExpand
  • 159
  • 6
Use of low molecular weight heparin in pregnancy.
In a controlled study of 15 pregnant patients undergoing therapeutic termination of pregnancy, seven received subcutaneously 5,000 anti-FXa units of low molecular weight (LMW) heparin 15 and 3 hExpand
  • 117
  • 6
Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability.
PURPOSE To investigate the effects of radiation on the endothelial cytoskeleton and endothelial monolayer permeability and to evaluate associated signaling pathways, which could reveal potentialExpand
  • 60
  • 5
The endothelial cytoskeleton as a target of electroporation-based therapies
Electroporation-based therapies, such as electrochemotherapy and electrogene therapy, result in the disruption of blood vessel networks in vivo and cause changes in blood flow and vascularExpand
  • 92
  • 5
Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.
Tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumor susceptibility to these agents are poorly understood. WeExpand
  • 91
  • 4
Tumour vascular disrupting agents: combating treatment resistance.
A large group of tubulin-binding microtubule-depolymerizing agents act as tumour vascular disrupting agents (VDAs). Several members of this group are now in clinical trials in combination withExpand
  • 71
  • 2